CIK 0001819133 · Non-accelerated filer<br>Smaller reporting company
Tango Therapeutics, Inc.
Sign in to watch- Ticker
- TNGX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (857) 320-4900
- Business address
- 201 BROOKLINE AVENUE, SUITE 901, BOSTON, MA, 02215
- Former names
- BCTG Acquisition Corp.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,858,086
- in 6 filings, $1.9M under 10b5-1 plans
Net −$1,858,086. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 18 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-01 | Crystal Adam President, R&D | Option exercise · Stock Option (Right to Buy) 10b5-1 | −27,000 | 341,040 | ||
| 2026-05-01 | Crystal Adam President, R&D | Option exercise 10b5-1 | +27,000 | $5.20 | $140K | 142,743 |
| 2026-05-01 | Crystal Adam President, R&D | Sale 10b5-1 | −25,900 | $21.19 | $549K | 116,843 |
| 2026-05-01 | Crystal Adam President, R&D | Sale 10b5-1 | −1,100 | $22.00 | $24K | 115,743 |
| 2026-05-01 | Crystal Adam President, R&D | Option exercise · Stock Option (Right to Buy) 10b5-1 | −27,000 | 368,040 | ||
| 2026-05-01 | Gall Matthew Chief Financial Officer | Grant or award | +40,000 | 40,000 | ||
| 2026-05-01 | Gall Matthew Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +240,000 | 240,000 | ||
| 2026-04-29 | Lee Sung Director | Grant or award | +12,300 | 22,300 | ||
| 2026-04-29 | Lee Sung Director | Grant or award · Stock Option (Right to Buy) | +5,200 | 5,200 | ||
| 2026-04-15 | Crystal Adam President, R&D | Option exercise 10b5-1 | +38,460 | $5.20 | $200K | 151,082 |
| 2026-04-15 | Crystal Adam President, R&D | Sale 10b5-1 | −38,460 | $25.00 | $962K | 112,622 |
| 2026-04-15 | Crystal Adam President, R&D | Option exercise · Stock Option (Right to Buy) 10b5-1 | −38,460 | 395,040 | ||
| 2026-04-01 | Crystal Adam President, R&D | Option exercise 10b5-1 | +27,000 | $5.20 | $140K | 139,622 |
| 2026-04-01 | Crystal Adam President, R&D | Sale 10b5-1 | −27,000 | $21.20 | $572K | 112,622 |
| 2026-04-01 | Crystal Adam President, R&D | Option exercise · Stock Option (Right to Buy) 10b5-1 | −27,000 | 433,500 | ||
| 2026-03-25 | Crystal Adam President, R&D | Option exercise 10b5-1 | +12,000 | $5.20 | $62K | 124,622 |
| 2026-03-25 | Crystal Adam President, R&D | Sale 10b5-1 | −12,000 | $20.11 | $241K | 112,622 |
| 2026-03-25 | Crystal Adam President, R&D | Option exercise · Stock Option (Right to Buy) 10b5-1 | −12,000 | 460,500 | ||
| 2026-03-05 | Crystal Adam President, R&D | Sale 10b5-1 | −20,251 | $15.00 | $304K | 112,622 |
| 2026-02-25 | Crystal Adam President, R&D | Sale 10b5-1 | −54,345 | $12.77 | $694K | 132,873 |
Page 3 of 11 · 211 trades